Understanding the Market | ESSEX BIO-TECH surged nearly 16% during the session, rising over 60% in the past month as Bevacizumab reached the primary clinical endpoint in Phase III

ESSEX BIO-TECH's stock price rose nearly 16% during the session, with a cumulative increase of over 60% since March 27. As of the time of writing, the stock price is up 11.52%, at HKD 4.55, with a trading volume of HKD 14.6944 million. The company's HLX04-O (Bevacizumab) has shown efficacy comparable to Ranibizumab and good safety in Phase III clinical trials in Chinese patients. An international multicenter Phase III clinical study is ongoing, with a new drug application expected to be submitted in 2025